Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
66High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05146973CT.gov External Beam Therapy With Theranostic Radioligand Therapy for Oligometastatic Prostate Cancer (ProstACT TARGET) | — | Completed | — | — | — |
NCT04946370CT.gov Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT04886986CT.gov Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT04576871CT.gov Re-treatment 225Ac-J591 for mCRPC | — | Completed | — | — | — |
NCT03545165CT.gov 177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC | — | Terminated | — | — | — |
NCT03276572CT.gov Phase I Trial of 225Ac-J591 in Patients With mCRPC | — | Completed | — | — | — |
NCT00859781CT.gov 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT00916123CT.gov Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer | — | Completed | — | — | — |
NCT00538668CT.gov Radioimmunotherapy in Prostate Cancer Using 177Lu-J591 Antibody | — | Completed | — | — | — |
NCT00195039CT.gov Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rosopatamab (this asset) | Telix Pharmaceuticals (Innovations) Pty Limited | P2 | BB · 64 |
| Flotufolastat F 18 | Washington University School of Medicine | P4 | BBB |
| AVOLVE | Masonic Cancer Center, University of Minnesota | P4 | BBB |
| Degarelix | Bayer | P4 | BBB |
| Estramustine | The University of Texas Health Science Center, Houston | P3 | BBB |
| Avodart | Bay State Clinical Trials, Inc. | P4 | BB |
| Goserelin | Bayer | P4 | BB |
| Prednisone | Mayo Clinic | P4 | BB |
| Flutamide | VA Office of Research and Development | P4 | BB |
+42 more in the Prostate Cancer cohort
Other indications for Rosopatamab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Neoplasm | — | P2 | CCC · 50 |
| Glioma | — | P1 | CC · 47 |
| Kidney Cancer | — | P1 | CC · 42 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rosopatamab in Prostate Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 15, 2026. https://terminal.floatz.ai/assets/rosopatamab-prostate-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →